3 results about "Thermogenesis" patented technology

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

This invention discloses the application of a Dickkopf-related protein 3 regulator in the preparation of metabolic regulation products. This invention is the first to propose and verify the novel functions of exogenous Dickkopf-related protein 3 in the regulation of adipose thermogenesis and the regulation of energy metabolism homeostasis in the body. It clarifies that it can promote lipid decomposition in adipocytes, enhance the thermogenic activity of adipocytes, promote the browning of white adipose tissue, and exert its effects through a non-UCP1-dependent pathway that promotes the stability of SERCA2b protein. This provides a new target and technical means for the intervention of lipid metabolism disorders such as obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease.

The present disclosure relates to the field of microbial therapy, and specifically to a product for preventing and / or treating obesity and a metabolic syndrome. The product includes a Lactobacillus acidophilus strain JYLA-126 and a coating solution thereof. A bacterial solution of the L. acidophilus strain JYLA-126 is coated with a bacterial coating solution to better transport the bacterial solution to the intestinal tract to exert therapeutic effects. The L. acidophilus strain JYLA-126 coating solution is used for intragastric treatment of obesity mice induced by high-fat diet. Various indicators show that the L. acidophilus strain JYLA-126 coating solution may effectively regulate intestinal microflora and maintain intestinal health. The coating solution improves liver glucose metabolism, reduces liver oxidative stress, improves liver lipid metabolism, and alleviates a liver inflammation level. This coating solution improves white adipose accumulation and promotes brown adipose thermogenesis, thereby achieving effective treatment of obesity and metabolic syndrome in mice.